Bench-to-bedside review: Preventive measures for contrast-induced nephropathy in critically ill patients

被引:0
作者
Guido van den Berk
Sanne Tonino
Carola de Fijter
Watske Smit
Marcus J Schultz
机构
[1] Onze Lieve Vrouwe Gasthuis,Resident, Department of Internal Medicine
[2] Onze Lieve Vrouwe Gasthuis,Internist, Department of Nephrology
[3] University of Amsterdam,Internist, Department of Nephrology, Academic Medical Center
[4] University of Amsterdam,Internist, Department of Intensive Care Medicine, Academic Medical Center
来源
Critical Care | / 9卷
关键词
contrast-induced nephropathy; fenoldopam; haemodialysis; haemofiltration; intensive care medicine; -acetylcysteine; sodium bicarbonate; theophylline;
D O I
暂无
中图分类号
学科分类号
摘要
An increasing number of diagnostic imaging procedures requires the use of intravenous radiographic contrast agents, which has led to a parallel increase in the incidence of contrast-induced nephropathy. Risk factors for development of contrast-induced nephropathy include pre-existing renal dysfunction (especially diabetic nephropathy and multiple myeloma-associated nephropathy), dehydration, congestive heart failure and use of concurrent nephrotoxic medication (including aminoglycosides and amphotericin B). Because contrast-induced nephropathy accounts for a significant increase in hospital-acquired renal failure, several strategies to prevent contrast-induced nephropathy are currently advocated, including use of alternative imaging techniques (for which contrast media are not needed), use of (the lowest possible amount of) iso-osmolar or low-osmolar contrast agents (instead of high-osmolar contrast agents), hyperhydration and forced diuresis. Administration of N-acetylcysteine, theophylline, or fenoldopam, sodium bicarbonate infusion, and periprocedural haemofiltration/haemodialysis have been investigated as preventive measures in recent years. This review addresses the literature on these newer strategies. Since only one (nonrandomized) study has been performed in intensive care unit patients, at present it is difficult to draw firm conclusions about preventive measures for contrast-induced nephropathy in the critically ill. Further studies are needed to determine the true role of these preventive measures in this group of patients who are at risk for contrast-induced nephropathy. Based on the available evidence, we advise administration of N-acetylcysteine, preferentially orally, or theophylline intravenously, next to hydration with bicarbonate solutions.
引用
收藏
相关论文
共 412 条
[21]  
Lansky AJ(2004)Prevention of contrast media nephrotoxicity: the story so far Clin Radiol 59 381-184
[22]  
Kent KM(2000)Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine N Engl J Med 343 180-283
[23]  
Pichard AD(2002)Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy Catheter Cardiovasc Interv 57 279-303
[24]  
Satler LF(2002)Acetylcysteine and contrast agent-associated nephrotoxicity J Am Coll Cardiol 40 298-358
[25]  
Leon MB(2002)Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial) Am J Cardiol 89 356-2207
[26]  
Levy EM(2002)A randomized controlled trial of Nacetylcysteine to prevent contrast nephropathy in cardiac angiography Kidney Int 62 2202-1388
[27]  
Viscoli CM(2002)Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure J Am Coll Cardiol 40 1383-2118
[28]  
Horwitz RI(2003)A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study J Am Coll Cardiol 41 2114-341
[29]  
Rihal CS(2003)Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast Catheter Cardiovasc Interv 58 336-558
[30]  
Textor SC(2003)Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial JAMA 289 553-560